-transparent.png){kind=logo}
The addition of deoxyuridine (UDR) to fluorouracil (FU) or floxuridine (5-fluoro-2' deoxyuridine) (FUDR) produced a substantial increase in their toxicity in BDF1 mice. Antitumor assays using sarcoma 180 tumor-bearing mice showed a concomitant increase in tumor growth inhibition for the nucleoside-drug combination over identical doses of the single drug. However, no significant increase in antitumor activity with the combination treatment was demonstrated when equitoxic doses were given. Additional support for the therapeutic equality of the single and combination drug regimens was the similarity of the therapeutic indexes for each treatment regimen involving either fluorouracil or floxuridine. The results suggested that any therapeutic benefit achieved with the combination therapy could be duplicated with either fluorouracil or floxuridine at a higher dose.
J G Jato, and
L M Lake, and
E E Grunden, and
B M Johnson
February 1980,
Gan,
J G Jato, and
L M Lake, and
E E Grunden, and
B M Johnson
January 1992,
Cancer chemotherapy and pharmacology,
J G Jato, and
L M Lake, and
E E Grunden, and
B M Johnson
January 2009,
Zhejiang da xue xue bao. Yi xue ban = Journal of Zhejiang University. Medical sciences,
J G Jato, and
L M Lake, and
E E Grunden, and
B M Johnson
January 1992,
Cancer chemotherapy and pharmacology,
J G Jato, and
L M Lake, and
E E Grunden, and
B M Johnson
June 1980,
Cancer research,
J G Jato, and
L M Lake, and
E E Grunden, and
B M Johnson
March 1985,
Journal of the National Cancer Institute,
J G Jato, and
L M Lake, and
E E Grunden, and
B M Johnson
April 2000,
Biochemical pharmacology,
J G Jato, and
L M Lake, and
E E Grunden, and
B M Johnson
January 1986,
Advances in experimental medicine and biology,
J G Jato, and
L M Lake, and
E E Grunden, and
B M Johnson
January 1981,
Cancer treatment reports,
J G Jato, and
L M Lake, and
E E Grunden, and
B M Johnson
December 1978,
Gan,
